CytoMed Therapeutics Limited GDTC
0.96
0.05
5.49%
as of 25 Sep
- Market cap
- $10.8M
- P/E
- 0.0×
Follow GDTC
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+6 more quarters Free account |
21.54 | 9.89 | 5.81 | 5.17 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
3.92% | 4.53% | 5.63% | 5.80% | |
Debt/Equity |
0.04 | 0.05 | 0.07 | 0.07 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(3.47) | (4.18) | (1.94) | (1.59) | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
— | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(1.28) | (3.01) | (1.53) | (3.37) | |
Working Capital |
5.42 | 3.95 | 2.66 | 2.30 | |
Capital Expenditures |
(0.43) | (1.02) | (0.27) | (0.50) | |
Net Current Asset Value |
5.13 | 3.64 | 2.32 | 1.97 | |
| Other line items | |||||
Quick Ratio |
21.54 | 9.89 | 5.81 | 5.17 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.47 | 0.72 | 0.86 | 1.03 | |
Average Payables |
0.14 | 0.32 | 0.29 | 0.37 | |
Average Assets |
5.88 | 5.63 | 8.43 | 7.79 | |
Average Common Equity |
4.31 | 3.53 | 7.71 | 6.93 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates